By Nadejda Andreev, Vanja Misic, Howard Kim, Aaron Dulgar-Tulloch, and Nick Timmins
Scale-up is a major hurdle in the production of lentiviral vectors (LVV) for use in gene therapy as traditional methods for production involve transfection of adherent cells cultured in serum-containing medium. We have evaluated a suspension and serum-free adapted stable inducible LVV producer cell line (Broussau et al., Mol. Ther. 2008) for the production of 3rd generation LVVs carrying the GFP transgene.
- Optimize culture conditions for increased LVV yield
- Explore perfusion profiles for extended production
- Demonstrate process translation into stirred tank reactors